-
Be the first to like this
Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.
Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Published on
Randomized controlled trials (RCTs) are the gold standard for evaluating therapeutics in patient populations. The data collected during RCTs include a wealth of clinical measures, biomarkers, and tissue samples – the analysis of which can lead to the approval of new medicines that improve the lives of patients. The secondary use of these data can also fuel the discovery of novel targets and biomarkers that support precision medicine, but a lack of metadata standards creates substantial barriers to reuse.
For this talk, I will discuss the challenges that arise when aggregating diverse types of data from a large number of RCTs and present a case study in how to apply (meta)data standards for the scalable curation and integration of these data into an analysis ready form.
Be the first to like this
Login to see the comments